research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
Search
for
Sort by
Research
150-180 / 1000+ resultsresearch Safety and efficacy of ALRV5XR in men with androgenetic alopecia: A randomised, double-blinded, placebo-controlled clinical trial
ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.
research The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment.
Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
research Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA)
Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
research Variable Clinical Features of Temporal Triangular Alopecia
Temporal triangular alopecia may be linked to sebaceous nevus and shows a new pinkish background feature.
research Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
research 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
research Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
research Acute telogen effluvium onset event is associated with the presence of female androgenetic alopecia: potential therapeutic implications
ATE is linked to FAA, and treatment depends on cause; minoxidil helps, finasteride may worsen.
research Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis
Atorvastatin is less effective for women with Hashimoto's thyroiditis.
research 7410 Bevacizumab Induced Hypothyroidism
Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research Iatrogenic Cushing Syndrome and Secondary Adrenal Insufficiency Due to an Interaction Between Fluticasone and Ritonavir
A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.
research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
research Unraveling Evolutionary Insights into AVT Peptide Conservation and Antimicrobial Motif Prediction Across Taxa
AVT is highly conserved and may have antimicrobial properties.
research Fetal Arrhythmia with a Myriad of Complications
Early diagnosis and management of congenital heart block in mothers with autoimmune conditions are crucial for improving neonatal outcomes.
research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
research Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
research Terminalia bellirica (Gaertn.) Roxb. extracts reshape the perifollicular microenvironment and regulate the MAPK pathway for androgenetic alopecia treatment
Terminalia bellirica extracts effectively promote hair regrowth and treat androgenetic alopecia.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Rapid Intravenous Administration of Corticotropin as a Test of Adrenocortical Insufficiency
The rapid corticotropin test is a quick and simple way to diagnose adrenal insufficiency.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research Trichotillomania treated with n-acetylcysteine
N-acetylcysteine may help treat trichotillomania.
research DOES PSADT AFTER RADICAL PROSTATECTOMY PREDICT OVERALL SURVIVAL?—A REPORT FROM THE SEARCH DATABASE GROUP
Shorter PSADT after prostate surgery is linked to higher risk of death.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
Ritlecitinib was generally well tolerated in children with alopecia areata.
research Temporal Triangular Alopecia—Clinical and Dermoscopic Features of a Rare Entity
Temporal triangular alopecia is a harmless, non-progressive hair loss condition.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
research Association Between Alopecia Areata and High‐Sensitivity Cardiac Troponin T as a Marker of Subclinical Myocardial Injury
Alopecia areata may be linked to higher heart disease risk.